A Phase 2 interventional study of lurbinectedin (PM01183) in Solid Tumors, sponsored by PharmaMar. Completed at 16 sites in 2 countries. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by PharmaMar · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
Drug: lurbinectedin (PM01183)
Change in QTcF (QT Corrected According to Fridericia's Formula)
ΔQTCF (Change in QTcF); EOI (end of infusion); LSM (Least Square Means); PK (Pharmacokinetic(s)). On Day 1 (D1) of Cycle 1 (C1), LSM ΔQTcF should have low difference values, without any clear trend to change with time. Therefore, the upper bound (UB) of the (two-sided) 90%Confidence Interval (CI) at all time points had to be less than the protocol-specified cut-off of 20 ms at each time point. If so, non-inferiority of any ECG time point to baseline with respect of QTc prolongation could be concluded
Time frame: Scheduled post-baseline ECG time points were taken 5-10 min before their time-matched PK samples: i.e., 5 min before EOI, 30 min, 1, 3, 24, 72 and 168 hours after EOI of Cycle 1, and 5 min before EOI, 30 min, 1, 3 and 168 hours after EOI of Cycle 2.
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration)
ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.
Time frame: Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Predicted ΔQTcF)
ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.
Time frame: Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Intercept)
ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.
Time frame: Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)
This study was nested into a multicenter clinical trial with a competitive recruitment. From August 2015 to June 2016, a total of 39 evaluable patients at 12 sites in USA and Spain were included in this QT evaluation study with baseline and one or more postbaseline Electrocardiogram (ECG) assessments available.
| Milestone | Group A - Lurbinectedin (PM01183) |
|---|---|
| Started | 39 |
| Completed | 32 |
| Not completed | 7 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Disease progression | 2 |
ΔQTCF (Change in QTcF); EOI (end of infusion); LSM (Least Square Means); PK (Pharmacokinetic(s)). On Day 1 (D1) of Cycle 1 (C1), LSM ΔQTcF should have low difference values, without any clear trend to change with time. Therefore, the upper bound (UB) of the (two-sided) 90%Confidence Interval (CI) at all time points had to be less than the protocol-specified cut-off of 20 ms at each time point. If so, non-inferiority of any ECG time point to baseline with respect of QTc prolongation could be concluded
| ms (Milliseconds) | Group A - Lurbinectedin (PM01183) |
|---|---|
| Cycle 1 - 5 min before EOI | 3.32 (1.12 to 5.51) |
| Cycle 1 - 30 min after EOI | 1.76 (-0.41 to 3.93) |
| Cycle 1 - 1 hour after EOI | 1.84 (-1.02 to 4.69) |
| Cycle 1 - 3 hour after EOI | 1.32 (-1.40 to 4.05) |
| Cycle 1 - 24 hour after EOI | -8.24 (-11.2 to -5.26) |
| Cycle 1 - 72 hour after EOI | -12.4 (-15.4 to -9.39) |
| Cycle 1 - 168 hour after EOI | -5.20 (-7.98 to -2.41) |
| Cycle 2 - Before start of infusion | -0.46 (-3.27 to 2.35) |
| Cycle 2 - 5 min before EOI | 2.25 (-1.18 to 5.68) |
| Cycle 2 - 30 min after EOI | 2.32 (-1.02 to 5.66) |
| Cycle 2 - 1 hour after EOI | 2.73 (-1.08 to 6.54) |
| Cycle 2 - 3 hour after EOI | 5.39 (1.17 to 9.60) |
| Cycle 2 - 168 hour after EOI | -4.22 (-7.36 to -1.08) |
ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.
| Microgram/milliliter (μg/mL) | Group A - Lurbinectedin (PM01183) |
|---|---|
| Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration) | 2.06 (1.42 to 2.71) |
ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.
| Milliseconds (ms) | Group A - Lurbinectedin (PM01183) |
|---|---|
| Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Predicted ΔQTcF) | 2.94 (0.79 to 5.10) |
ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.
| Unitless | Group A - Lurbinectedin (PM01183) |
|---|---|
| Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Intercept) | -6.40 (-8.44 to -4.35) |
Collected over Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A - Lurbinectedin (PM01183) | 13/39 (33.3%) | 9/39 (23.1%) | 35/39 (89.7%) |
| Event | Group A - Lurbinectedin (PM01183) |
|---|---|
| Abdominal painGastrointestinal disorders | 3/39 |
| Blood calcium decreasedInvestigations | 1/39 |
| Blood phosphorus decreasedInvestigations | 1/39 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/39 |
| AspirationRespiratory, thoracic and mediastinal disorders | 1/39 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/39 |
| Facial paralysisNervous system disorders | 1/39 |
| General physical health deteriorationGeneral disorders | 1/39 |
| Small intestinal obstructionGastrointestinal disorders | 1/39 |
| CholangitisHepatobiliary disorders | 1/39 |
| Event | Group A - Lurbinectedin (PM01183) |
|---|---|
| NauseaGastrointestinal disorders | 19/39 |
| FatigueGeneral disorders | 15/39 |
| ConstipationGastrointestinal disorders | 8/39 |
| VomitingGastrointestinal disorders | 7/39 |
| NeutropeniaBlood and lymphatic system disorders | 6/39 |
| Abdominal painGastrointestinal disorders | 6/39 |
| HeadacheNervous system disorders | 4/39 |
| PyrexiaGeneral disorders | 4/39 |
| Decreased appetiteMetabolism and nutrition disorders | 4/39 |
| AnaemiaBlood and lymphatic system disorders | 3/39 |
| Age, Categorical(Participants) | Group A - Lurbinectedin (PM01183) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 37 |
| >=65 years | 2 |
| Age, Continuous(years) | Group A - Lurbinectedin (PM01183) |
|---|---|
| Median | 56 (28 to 65) |
| Sex: Female, Male(Participants) | Group A - Lurbinectedin (PM01183) |
|---|---|
| Female | 22 |
| Male | 17 |
| Region of Enrollment(Participants) | Group A - Lurbinectedin (PM01183) |
|---|---|
| United States | 14 |
| Spain | 25 |
Ran from Aug 2015 to primary completion in Aug 2016, 12 months.
Results were first posted in Feb 2019, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183